T2 Biosystems Inc (NASDAQ:TTOO) – Analysts at Leerink Swann issued their Q1 2018 earnings per share estimates for T2 Biosystems in a research note issued to investors on Wednesday, according to Zacks Investment Research. Leerink Swann analyst P. Souda anticipates that the medical equipment provider will post earnings of ($0.35) per share for the quarter. Leerink Swann also issued estimates for T2 Biosystems’ Q2 2018 earnings at ($0.34) EPS, Q3 2018 earnings at ($0.34) EPS, Q4 2018 earnings at ($0.34) EPS, FY2018 earnings at ($1.38) EPS and FY2019 earnings at ($1.25) EPS.
Other analysts also recently issued research reports about the company. HC Wainwright set a $8.00 target price on T2 Biosystems and gave the company a “buy” rating in a research note on Wednesday, March 7th. Zacks Investment Research raised T2 Biosystems from a “hold” rating to a “buy” rating and set a $7.25 price objective on the stock in a research note on Thursday, March 22nd. Goldman Sachs began coverage on T2 Biosystems in a research note on Monday, January 29th. They issued a “neutral” rating and a $5.20 price objective on the stock. Finally, ValuEngine raised T2 Biosystems from a “strong sell” rating to a “sell” rating in a research note on Monday, March 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $6.12.
TTOO traded down $0.17 on Friday, hitting $6.32. 171,916 shares of the company’s stock traded hands, compared to its average volume of 334,903. The company has a market capitalization of $233.77, a PE ratio of -3.08 and a beta of 1.19. T2 Biosystems has a one year low of $2.50 and a one year high of $7.26. The company has a current ratio of 0.86, a quick ratio of 0.83 and a debt-to-equity ratio of 1.29.
Large investors have recently added to or reduced their stakes in the business. Gagnon Securities LLC bought a new stake in T2 Biosystems in the 3rd quarter worth approximately $396,000. Lagoda Investment Management L.P. increased its stake in T2 Biosystems by 61.4% in the 3rd quarter. Lagoda Investment Management L.P. now owns 3,188,539 shares of the medical equipment provider’s stock worth $13,392,000 after acquiring an additional 1,212,618 shares during the last quarter. Senvest Management LLC increased its stake in T2 Biosystems by 17.6% in the 3rd quarter. Senvest Management LLC now owns 3,337,946 shares of the medical equipment provider’s stock worth $14,019,000 after acquiring an additional 500,000 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in T2 Biosystems in the 3rd quarter worth approximately $630,000. Finally, Renaissance Technologies LLC increased its stake in T2 Biosystems by 72.2% in the 4th quarter. Renaissance Technologies LLC now owns 83,500 shares of the medical equipment provider’s stock worth $344,000 after acquiring an additional 35,000 shares during the last quarter. 52.32% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “T2 Biosystems Inc Expected to Earn Q1 2018 Earnings of ($0.35) Per Share (NASDAQ:TTOO)” was originally published by Enterprise Leader and is the property of of Enterprise Leader. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://theenterpriseleader.com/2018/04/02/t2-biosystems-inc-nasdaqttoo-expected-to-earn-q1-2018-earnings-of-0-35-per-share.html.
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.